Effects of Lisdexamfetamine Dimesylate on the Functioning of College Students With Attention-deficit/Hyperactivity Disorder (ADHD)

• Behavior Rating Inventory of Executive Function-Adult Version [ Time Frame: Participants will complete this measure once per week for the five consecutive weeks that they are enrolled in the study ] [ Designated as safety issue: No ]
• Side-Effects Rating Scale [ Time Frame: Participants will complete this measure once per week for the five consecutive weeks that they are enrolled in the study ] [ Designated as safety issue: Yes ]
  Self-report of possible adverse events associated with placebo or active dosage of lisdexamfetamine
• Social Adjustment Scale-Self-Report [ Time Frame: Participants will complete this measure once per week for the five consecutive weeks that they are enrolled in the study ] [ Designated as safety issue: No ]
  Self-report of social functioning
• Conners Continuous Performance Test [ Time Frame: Participants will complete this measure once per week for the five consecutive weeks that they are enrolled in the study ] [ Designated as safety issue: No ]
  Direct assessment of sustained attention and impulse control
• Self-report of study and organizational skills [ Time Frame: Participants will complete this measure once per week for the five consecutive weeks that they are enrolled in the study ] [ Designated as safety issue: No ]
• Self-report of alcohol and illicit drug use [ Time Frame: Participants will complete this measure once per week for the five consecutive weeks that they are enrolled in the study ] [ Designated as safety issue: Yes ]

The purpose of this study is to evaluate the effects of lisdexamfetamine dimesylate, a prodrug stimulant, on the behavioral, academic, and psychosocial functioning of college students with attention-deficit/hyperactivity disorder (ADHD). Twenty-five college students with ADHD from two universities (University of Rhode Island and Lehigh University) will complete a within-subject, placebo-controlled research trial. Dependent measures tapping behavioral, psychosocial, and academic functioning will be completed on a weekly basis across five conditions (baseline, placebo, and 30-mg, 50-mg, and 70-mg lisdexamfetamine).

Inclusion Criteria:

• DSM-IV-TR criteria for ADHD based on self- and parent-report using questionnaires and clinical interview

Exclusion Criteria:

• significant cardiac condition based on medical history and/or physical examination
• significant substance abuse based on self-report and toxicology screen at intake
• significant symptoms of major depressive disorder, bipolar disorder, or thought disorder based on initial diagnostic interview